Atossa Gets FDA Rare Pediatric Disease Tag For (Z)-Endoxifen In McCune-Albright Syndrome

Atossa Therapeutics said the FDA granted Rare Pediatric Disease designation to (Z)-endoxifen for treatment of McCune-Albright Syndrome in females. The designation is a regulatory positive for the program and may enhance its development and commercialization prospects, but the announcement is limited to a status update rather than an approval or trial result. Market impact should be modest.

Analysis

Atossa Therapeutics said the FDA granted Rare Pediatric Disease designation to (Z)-endoxifen for treatment of McCune-Albright Syndrome in females. The designation is a regulatory positive for the program and may enhance its development and commercialization prospects, but the announcement is limited to a status update rather than an approval or trial result. Market impact should be modest.